Ergomed plc Award of share options (3455T)
03 July 2018 - 4:00PM
UK Regulatory
TIDMERGO
RNS Number : 3455T
Ergomed plc
03 July 2018
PRESS RELEASE
Ergomed award of share options to Directors and Company
Secretary
London, UK - 3 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or
the "Company") a company focused on providing specialised services
to the pharmaceutical industry, today announces that the following
LTIP (Long Term Investment Plan) awards have been made to
newly-appointed CFO Stuart Jackson, COO Jan Petracek, and General
Counsel and Company Secretary Sanja Juric.
The awards consist of share options over the Company's ordinary
shares having a nominal value of 1 pence each (the "Options") with
an exercise price of 1 pence per share. Of the total, 50% of the
Options will vest after three years and are not subject to
performance criteria. The remaining 50% will vest based on total
shareholder return over the three year vesting period with a
minimum of 15 per cent. per annum. Once vested the options will be
exercisable until 1 July 2028.
Director / Executive Award of Options Resulting interest Current shareholding
in options in the Company
Stuart Jackson,
Chief Financial Officer 400,000 400,000 1,845
----------------- ------------------- ---------------------
Jan Petracek, Chief
Operations Officer 400,000 450,000 418,006
----------------- ------------------- ---------------------
Sanja Juric, General
Counsel and Company
Secretary * 25,000 175,000 Nil
----------------- ------------------- ---------------------
* Sanja Juric also holds 150,000 options over shares owned by Dr
Miroslav Reljanovic.
In total 825,000 Options were granted yesterday, representing
1.8 per cent. of the issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name 1) Stuart Jackson
2) Jan Petracek
3) Sanja Juric
----------------------------------- --------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position/status 1) Chief Financial Officer
2) Chief Operations Officer
3) General Counsel and Company Secretary
----------------------------------- --------------------------------------------------
b) Initial notification 1) Initial Notification
/Amendment 2) Initial Notification
3) Initial Notification
----------------------------------- --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name Ergomed Plc
----------------------------------- --------------------------------------------------
b) Legal Entity 213800BVS8I9VMC1AP84
Identifier
----------------------------------- --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument GB00BN7ZCY67
Identification
code
----------------------------------- --------------------------------------------------
b) Nature of Award of options
the transaction
----------------------------------- --------------------------------------------------
c) Currency GBP
----------------------------------- --------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
----------------------------------- --------------------------- ---------------------
1) Nil 400,000
-------------------------------------------------------------------- ---------------------
2) Nil 450,000
-------------------------------------------------------------------- ---------------------
3) Nil 175,000
-------------------------------------------------------------------- ---------------------
e) Aggregated 1) 400,000 ordinary shares of 1 pence each,
information nil consideration
- Aggregated 2) 450,000 ordinary shares of 1 pence each,
volume nil consideration
- Price 3) 175,000 ordinary shares of 1 pence each,
- Aggregated nil consideration
total
----------------------------------- --------------------------------------------------
f) Date of the 03 July 2018
transaction
----------------------------------- --------------------------------------------------
g) Place of the Outside a trading venue
transaction
----------------------------------- --------------------------------------------------
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Ivar Milligan / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSIEFEFASEDW
(END) Dow Jones Newswires
July 03, 2018 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024